Genotype & phenotype in Lowe Syndrome: specific OCRL1 patient mutations differentially impact cellular phenotypes. Issue 3 (30th January 2021)

• Record Type: Journal Article
• Authors: Ramadesikan, Swetha; Skiba, Lisette; Lee, Jennifer; Madhivanan, Kayalvizhi; Sarkar, Daipayan; De La Fuente, Agustina; Hanna, Claudia B; Terashi, Genki; Hazbun, Tony; Kihara, Daisuke; Aguilar, R Claudio
• Is Part Of: Human molecular genetics. Volume 30:Issue 3/4(2021)
• Page Start: 198
• Page End: 212
• Publication Date: 2021-01-30
• Subjects: Human molecular genetics -- Periodicals; Human chromosome abnormalities -- Periodicals; 572.8
• DOI: 10.1093/hmg/ddab025
• Languages: English
• ISSNs: 0964-6906

Abstract

Abstract: Lowe Syndrome (LS) is a lethal genetic disorder caused by mutations in the OCRL1 gene which encodes the lipid 5′ phosphatase Ocrl1. Patients exhibit a characteristic triad of symptoms including eye, brain and kidney abnormalities with renal failure as the most common cause of premature death. Over 200 OCRL1 mutations have been identified in LS, but their specific impact on cellular processes is unknown. Despite observations of heterogeneity in patient symptom severity, there is little understanding of the correlation between genotype and its impact on phenotype. Here, we show that different mutations had diverse effects on protein localization and on triggering LS cellular phenotypes. In addition, some mutations affecting specific domains imparted unique characteristics to the resulting mutated protein. We also propose that certain mutations conformationally affect the 5′-phosphatase domain of the protein, resulting in loss of enzymatic activity and causing common and specific phenotypes (a conformational disease scenario). This study is the first to show the differential effect of patient 5′-phosphatase mutations on cellular phenotypes and introduces a conformational disease component in LS. This work provides a framework that explains symptom heterogeneity and can help stratify patients as well as to produce a more accurate prognosis depending on the nature and location of the mutation within the OCRL1 gene.